Catalent Inc (CTLT)

[Trend-Setter]

"Having sublingual, nasal and/or oral solid vaccine dosage forms suitable for storage under all world climates represent major innovations and will have important impacts for therapeutic and prophylactic vaccines. These non-invasive vaccine administration routes are expected to elicit the immune response in the relevant immune compartments (blood and/or mucosa) and may offer the major advantage of needle-free vaccination, a painless approach favoring a broader population acceptance. Eliminating syringes, needles and vials with diluents for vaccine reconstitution or adjuvant preparation would also lower the production costs, rendering vaccine handling safer with a simplified logistics".

"Other existing virosomal vaccines or vaccines obtained by different technologies could benefit from MACIVIVA with minimal efforts to obtain similar solid vaccine forms. Due to the ease of administration of solid vaccine forms for non-invasive routes, gradual replacement of liquid and lyophilized/reconstituted vaccines by needle-free vaccines is expected, favoring higher immunization coverage for the great benefit of the overall health care system".

https://cordis.europa.eu/docs/results/h2020/646/646122_PS/maciviva-project-concept.jpg

https://cordis.europa.eu/result/rcn/194900_en.html

This project is expected to concludes this October 2018 (42 months) and final data reporting follows.